Drugs / G-CSF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07044544 Background | Jul 2025 → Dec 2026 expected | acute myeloid leukemia, myelodysplastic syndrome | University of Alabama at Birmingham | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07044544 ↗ |
| Modality | Protein / enzyme biologic | “G-CSF) is a glycoprotein” NCT07044544 ↗ |
| Route | Subcutaneous | “G-CSF will be administered subcutaneously on days -14 to -10 at a dose of 5mcg/kg.” NCT07044544 ↗ |